Toronto association

Phase 3Small molecule

EEMS

Toronto association is one of 10 small molecule programs targeting Premature Ejaculation. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Premature EjaculationNot yet recruiting

Premature EjaculationPhase 3

Not yet recruiting

Competition

Competitive Landscape

11 competitors in Premature Ejaculation

#DrugCompanyPhaseTrials

Viagra

VViatris Specialty LLC

Approved

1 2

Xylocaine

MMEDRx USA, Inc.

Approved

1 3

Botox

AbbVie

Phase 3

1 4

Standard Treatment

Boehringer Ingelheim

Phase 3

1 5

Toronto association

EEMS

Phase 3

1 6

BP1.4979

BBioprojet

Phase 2

1 7

Botox

RRevance Therapeutics, Inc.

Preclinical

1 8

Dapoxetine Hydrochloride

Johnson & Johnson

Preclinical

2 9

Bont-a

SSir Run Run Shaw Hospital

Preclinical

1 10

Serotonin Reuptake Inhibitor (SSRI)

MMedipol University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Premature Ejaculation1 trial

Efficacy and Safety of Toronto Association in the Treatment of Erectile Dysfunction and Premature Ejaculation

Not yet recruiting·EEMS·Phase 3·NCT05052879·232 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Toronto association. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Toronto association compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Toronto association. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — EMS company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EEMS

Toronto association

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Premature Ejaculation1 trial

References

Drug Info

Quick Facts

Related News